Decreased dihydropyrimidine dehydrogenase enzyme activity is associated with severe fluoropyrimidine-associated toxicity. Four clinically relevant variants in the DPYD gene are associated with decreased dihydropyrimidine dehydrogenase activity. However, only similar to 25% of DPYD variant carriers show a decreased dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells. Objective To investigate if dihydropyrimidine dehydrogenase phenotyping has added value when combined with DPYD genotyping in predicting fluoropyrimidine-related toxicity. Methods Retrospective cohort study in which treatment and toxicity data were collected of 228 patients genotyped for four DPYD variants and phenotyped using an ex vivo peripheral blo...
Fluoropyrimidines, the mainstay agents for the treatment of colorectal cancer, alone or as a part o...
5-Fluorouracil (5-FU) and capecitabine (CAP) are among the most frequently prescribed anticancer dru...
Carriers of the genetic DPYD*2A variant, resulting in dihydropyrimidine dehydrogenase deficiency, ar...
Decreased dihydropyrimidine dehydrogenase enzyme activity is associated with severe fluoropyrimidine...
Among cancer patients treated with fluoropyrimidines, 10–40% develop severe toxicity. Polymorphism o...
Objective: Fluoropyrimidine treatment can be optimized based on dihydropyrimidine dehydrogenase (DPD...
DPYD genotyping prior to fluoropyrimidine treatment is increasingly implemented in clinical care. Wi...
DPYD genotyping prior to fluoropyrimidine treatment is increasingly implemented in clinical care. Wi...
We investigated the clinical relevance of dihydropyrimidine dehydrogenase gene (DPYD) variants to pr...
Background: Fluoropyrimidine is widely used owing to its clinical efficacy, however, patients with d...
Chemotherapeutic use of 5-fluorouracil (5FU) is compromised by 10-20% of patients developing severe ...
5-Fluorouracil (5-FU) and capecitabine (CAP) are among the most frequently prescribed anticancer dru...
The dihydropyrimidine dehydrogenase enzyme (DPD, encoded by the gene DPYD) plays a key role in the m...
The dihydropyrimidine dehydrogenase enzyme (DPD, encoded by the gene DPYD) plays a key role in the m...
Purpose: Dihydropyrimidine dehydrogenase (DPD) is a critical determinant of 5-fluorouracil pharmacol...
Fluoropyrimidines, the mainstay agents for the treatment of colorectal cancer, alone or as a part o...
5-Fluorouracil (5-FU) and capecitabine (CAP) are among the most frequently prescribed anticancer dru...
Carriers of the genetic DPYD*2A variant, resulting in dihydropyrimidine dehydrogenase deficiency, ar...
Decreased dihydropyrimidine dehydrogenase enzyme activity is associated with severe fluoropyrimidine...
Among cancer patients treated with fluoropyrimidines, 10–40% develop severe toxicity. Polymorphism o...
Objective: Fluoropyrimidine treatment can be optimized based on dihydropyrimidine dehydrogenase (DPD...
DPYD genotyping prior to fluoropyrimidine treatment is increasingly implemented in clinical care. Wi...
DPYD genotyping prior to fluoropyrimidine treatment is increasingly implemented in clinical care. Wi...
We investigated the clinical relevance of dihydropyrimidine dehydrogenase gene (DPYD) variants to pr...
Background: Fluoropyrimidine is widely used owing to its clinical efficacy, however, patients with d...
Chemotherapeutic use of 5-fluorouracil (5FU) is compromised by 10-20% of patients developing severe ...
5-Fluorouracil (5-FU) and capecitabine (CAP) are among the most frequently prescribed anticancer dru...
The dihydropyrimidine dehydrogenase enzyme (DPD, encoded by the gene DPYD) plays a key role in the m...
The dihydropyrimidine dehydrogenase enzyme (DPD, encoded by the gene DPYD) plays a key role in the m...
Purpose: Dihydropyrimidine dehydrogenase (DPD) is a critical determinant of 5-fluorouracil pharmacol...
Fluoropyrimidines, the mainstay agents for the treatment of colorectal cancer, alone or as a part o...
5-Fluorouracil (5-FU) and capecitabine (CAP) are among the most frequently prescribed anticancer dru...
Carriers of the genetic DPYD*2A variant, resulting in dihydropyrimidine dehydrogenase deficiency, ar...